<DOC>
	<DOCNO>NCT02461563</DOCNO>
	<brief_summary>This study evaluate safety , pharmacokinetics ( PK ) , ability MK-1075 suppress viral load ( VL ) HCV-infected participant 7 day daily dose administration . The primary hypothesis once-daily dose sufficiently safe well tolerate HCV-infected participant , mean maximum HCV RNA ( log10 IU/mL ) reduction least 3 log10 IU/mL compare baseline follow multiple dose oral administration MK-1075 HCV genotype 1 ( GT1 ) genotype 3 ( GT3 ) infect participant .</brief_summary>
	<brief_title>A Multiple-Dose Study Evaluate MK-1075 Hepatitis C Virus ( HCV ) Infected Participants ( MK-1075-004 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Female nonchildbearing potential Have body mass index ( BMI ) &gt; =18 = &lt; 37 kg/m^2 Excepting HCV infection , good health Have clinical diagnosis chronic HCV infection , exclusively GT1 exclusively GT3 Agree follow smoke restriction Has history clinically significant , stably control endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary , major neurological abnormality disease . Have treat amiodarone within prior year , currently betablockers verapamil Has history cancer ( malignancy ) Has history significant multiple and/or severe allergy ( e.g. , food , drug , latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food Is positive hepatitis B surface antigen human immunodeficiency virus ( HIV ) Has major surgery , donate lose approximately 500 mL blood within 4 week prior screen visit Has participate another drug trial within 4 week prior screen visit Is take nonpermitted medication treat comorbid condition Consumes great 2 glass alcoholic beverage Is regular user cannabis , illicit drug history drug ( include alcohol ) abuse within approximately 12 month Has evidence history chronic hepatitis cause HCV , include limited nonHCV viral hepatitis , nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis Has treat HCV inhibitor , sofosbuvir VX135 Has evidence advance decompensated liver disease , bridge fibrosis high grade fibrosis prior liver biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>